Sarepta Therapeutics Inc

SRPT · Moat type: REGULIERUNG

MoatScore

3/10

Fair Value

n/a

Margin of Safety

n/a

Rating

BEOBACHTEN

Sarepta Therapeutics develops and markets RNA-based gene therapies and exon-skipping treatments for rare neuromuscular disorders, particularly Duchenne muscular dystrophy (DMD), and generates revenue primarily through the sale of these approved specialty therapeutics to a narrowly defined patient population in the United States and increasingly internationally.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.